Wednesday, March 09, 2022 4:23:11 PM
ATLnsider, good topic at this point in time. Just a general thought for investment purposes:
1) strong P3 data is needed for NWBO to have a long term future
2) well constructed company/platform development plans are needed for NWBO to have a long term future
If they announce both holding most NWBO makes a lot of sense.
If they announce decent but not strong data results without well constructed plans divesting most NWBO makes sense.
If they are somewhere between decent data and minimal plans and strong data with well done plans a balanced hold/divest approach may make sense.
One thing I will say for us long term longs here. Given the time that NWBO has provided to pre-think next investment steps, we have little reason not to be prepared, IMO. I am expecting strong data and well done plans, though I have more confidence in the data and less in the plans, at least until reachjo just mentioned the potential CRL strategic relationship that is very interesting and bumped up my expectations of their potential plans.
GLTA
1) strong P3 data is needed for NWBO to have a long term future
2) well constructed company/platform development plans are needed for NWBO to have a long term future
If they announce both holding most NWBO makes a lot of sense.
If they announce decent but not strong data results without well constructed plans divesting most NWBO makes sense.
If they are somewhere between decent data and minimal plans and strong data with well done plans a balanced hold/divest approach may make sense.
One thing I will say for us long term longs here. Given the time that NWBO has provided to pre-think next investment steps, we have little reason not to be prepared, IMO. I am expecting strong data and well done plans, though I have more confidence in the data and less in the plans, at least until reachjo just mentioned the potential CRL strategic relationship that is very interesting and bumped up my expectations of their potential plans.
GLTA
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
